“Sympathetic denervation remains an exciting therapy for a range of diseases but is currently plagued by clinical variability. CBSET is aiming to provide mechanistic data as a pathway to improve future efficacy.” – Peter M. Markham, President and CEO, CBSET
LEXINGTON, Mass., May 16, 2014 — Scientists at CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education, and advancement of medical technologies, will present preclinical data from the podium at “EuroPCR 2014.” These data expand CBSET’s understanding of the relationship between variable microanatomy and nerve distribution that can lead to intra-patient variability in efficacy post renal denervation, despite consistent delivery of thermal energy.
“In response to the recent controversies over the efficacy of renal sympathetic denervation, we are rapidly expanding our understanding of the mechanisms that will facilitate safer and more efficacious treatments using preclinical models. These data provide a critical piece of the puzzle for innovators to understand the relevant physiology, and to advance their approaches towards treating diseases involving sympathetic denervation and modulation,” said Peter Markham, President, CEO and co-founder of CBSET.
“CBSET is pioneering the understanding in the medical device community of the factors that govern efficacy with renal denervation therapies. We are equipping the medical device industry to further evolve its perspectives on and optimization of RDN and other ablative therapies,” added Elazer Edelman, M.D., Ph.D., chairman and co-founder of CBSET, who will make two podium presentations at EuroPCR on behalf of CBSET: (1) “The unique anatomy of renal arterial ostium may limit efficacy of endovascular radiofrequency ablation,” Wednesday, May 21, 9:51-10:03, Room 343; (2) “Computational methodology for understanding and predicting lesion geometry in catheter-based renal denervation,” Wednesday, May 21, 12:35-12:45 p.m., Room 342AB.
Dr. Rami Tzafriri, Principal Scientist and computational expert at CBSET, will also deliver a podium presentation: (3) “Electrode irrigation protects the artery wall while maintaining injury to renal nerves,” Wednesday, May 21, 9:27-9:39 a.m., Room 343.
CBSET’s novel approach to renal denervation was first presented at “TCT 2013” by Dr. Edelman* and combines quantitative histopathologic characterization of target microanatomy with computational modeling and a novel biomarker assay for the determination of norepinephrine in tissue. In these studies, temperature and injury gradients are predicted based on electrode power and duration, tissue architecture with associated heat conductivity, and heat clearance by blood flow. The animal model, bioanalytical assay, histopathological methods, and computational models are all critical tools developed by CBSET scientists that are being used to understand the tissue-level factors that contribute to efficacy.
“It is critical that we persist in amplifying our understanding of the mechanisms of sympathetic denervation to enable targeting of other diseases in which the sympathetic nervous system plays a pivotal function, such as heart failure and obstructive sleep apnea,” said Dr. Erica Smith, Scientific Director of Business Development at CBSET. “The data to be presented at EuroPCR will provide a further understanding of the variability in efficacy of sympathetic denervation for the treatment of drug-resistant hypertension, and a basis of understanding for the future application of thermal ablation therapies.”
For a copy of the EuroPCR abstracts and to learn more about the services provided by CBSET, contact Dr. Erica Smith, Director of Business Development at CBSET: +1-781-296-5319, email@example.com.
CBSET Inc. — 500 Shire Way, Lexington, MA 02421 — is the preclinical research leader in critically important therapeutic fields such as interventional cardiology, renal disease and dialysis, chronic drug-resistant hypertension, women’s health, minimally invasive surgery, orthopedics, biological and synthetic tissue repair, drug delivery, bioresorbable devices, and combination medical device and drug-eluting products.